Physician profile
Thomas M Browne
NPI 1548277288
$6,605.95
in general payments reported to CMS, 2019-2025
43 companies · $1,117 in 2025
The $1,117 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,054 · 2020: $410 · 2021: $1,181 · 2022: $983 · 2023: $765 · 2024: $1,095 · 2025: $1,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,966 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,966.26 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $960.75 | 2021-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $793.57 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $694.08 | 2019-2025 | Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $370.23 | 2022-2025 | Caplyta |
| Lilly USA, LLC | $368.81 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Corium, LLC | $297.60 | 2021-2024 | Azstarys, Adlarity, Adlarity |
| Pfizer INC. | $251.88 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.79 | 2019-2025 | Jardiance |
| Tris Pharma INC | $216.44 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $203.51 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $190.31 | 2025 | Fanapt |
| Allergan, INC. | $185.15 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $165.48 | 2019-2024 | |
| Supernus Pharmaceuticals, INC. | $160.52 | 2022-2024 | Qelbree |
| Bayer Healthcare Pharmaceuticals INC. | $133.22 | 2022-2025 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Browne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.